CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kymera Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kymera Therapeutics Inc
500 North Beacon Street, 4Th Floor
Phone: (857) 285-5314p:857 285-5314 WATERTOWN, MA  02472  United States Ticker: KYMRKYMR
Business Summary
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board, Co-Founder Bruce L.Booth 50 8/1/2017 9/1/2015
President, Chief Executive Officer, Co-Founder, Director NelloMainolfi 46 11/1/2019 11/1/2019
Chief Financial Officer Bruce N.Jacobs 55 9/19/2023 7/1/2019
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Kymera Securities Corporation
KYMERA THERAPEUTICS
KYMR

General Information
Number of Employees: 208 (As of 3/31/2025)
Outstanding Shares: 70,157,214 (As of 6/26/2025)
Shareholders: 18
Stock Exchange: NASD
Federal Tax Id: 812992166
Fax Number: (302) 655-5049
Email Address: inquiries@kymeratx.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, July 3, 2025